OBJECTIVE: To investigate the molecular mechanism of osteogenetic differentiation of bone-marrow mesenchymal stem cells (BMSCs) and the probability using the BMSCs to gene therapy for bone fractures. METHODS: By gradient centrifugation and adherence to the culture plastic, the MSCs were separated and purified from mouse bone marrow. The BMSCs then were cultured and sub-cultured in the osteogenetic medium (100 nmol/L Dexamethasone, 10 mmol/L beta-glycerophosphate and 50 mg/mL ascorbic acid, osteogenic supplements, OS-medium) or the recombinant human bone morphogenetic protein-2 (rhBMP-2, 500 ng/mL) for the mineralized inductions of osteogenesis, and stained by alizarin red in inducing week 1 and 2 for the identification of calcium nodule formed. The gene expressions of Runx2, Osx, OCN, and Col I were detected by RT-PCR on day 1, 2 and 3 after doing the osteogenetic inductions. RESULTS: The BMSCs induced by OS-medium and rhBMP-2 were both of positive Ca nodules with alizarin red. However, the Ca nodule induced by OS-medium formed in 1 inducing week, but the one done by rhBMP-2 occurred in 2 inducing weeks, which meant it was a late for one week. In the OS-group, the mRNA of Runx2 could not be detected on inducing day 1, 2 and 3, but the Osx mRNA appeared on inducing day 2 and 3, and also the mRNAs of OCN and Col I could be detected in all the three inducing days. In rhBMP-2 group, the Runx2 gene expressed on inducing day 2, the Osx gene expressed on inducing day 2 and 3, the OCN and Col I genes expressed on inducing day 1, 2 and 3. CONCLUSION: The BMSCs induced by OS-medium are more likely to form bone nodules than that of rhBMP-2, because of their simpler mechanisms to differentiate into osteoblasts.
OBJECTIVE: To investigate the molecular mechanism of osteogenetic differentiation of bone-marrow mesenchymal stem cells (BMSCs) and the probability using the BMSCs to gene therapy for bone fractures. METHODS: By gradient centrifugation and adherence to the culture plastic, the MSCs were separated and purified from mouse bone marrow. The BMSCs then were cultured and sub-cultured in the osteogenetic medium (100 nmol/L Dexamethasone, 10 mmol/L beta-glycerophosphate and 50 mg/mL ascorbic acid, osteogenic supplements, OS-medium) or the recombinant humanbone morphogenetic protein-2 (rhBMP-2, 500 ng/mL) for the mineralized inductions of osteogenesis, and stained by alizarin red in inducing week 1 and 2 for the identification of calcium nodule formed. The gene expressions of Runx2, Osx, OCN, and Col I were detected by RT-PCR on day 1, 2 and 3 after doing the osteogenetic inductions. RESULTS: The BMSCs induced by OS-medium and rhBMP-2 were both of positive Ca nodules with alizarin red. However, the Ca nodule induced by OS-medium formed in 1 inducing week, but the one done by rhBMP-2 occurred in 2 inducing weeks, which meant it was a late for one week. In the OS-group, the mRNA of Runx2 could not be detected on inducing day 1, 2 and 3, but the Osx mRNA appeared on inducing day 2 and 3, and also the mRNAs of OCN and Col I could be detected in all the three inducing days. In rhBMP-2 group, the Runx2 gene expressed on inducing day 2, the Osx gene expressed on inducing day 2 and 3, the OCN and Col I genes expressed on inducing day 1, 2 and 3. CONCLUSION: The BMSCs induced by OS-medium are more likely to form bone nodules than that of rhBMP-2, because of their simpler mechanisms to differentiate into osteoblasts.